Tuesday November 17th 2020


icometrix, a world leader in (imaging) AI solutions for people with brain disorders, received the 2020 EIT Digital Challenge award as the best European scaleup company for digital wellbeing.

icometrix was selected to the competition alongside 402 other scaleups from 32 European countries in the 7th annual edition of the EIT Digital Challenge, which targets European digital technology scaleups focused on the fast growth of their business in Europe and worldwide.

An esteemed jury of tech experts, venture capitalists, and business people selected icometrix as the winner in the category for Digital Wellbeing, one of the five strategic innovation areas, next to Digital Tech, Digital Industry, Digital Cities, and Digital Finance. icometrix will join the EIT Digital Accelerator that was recognized in 2019 as one of the five World Top Public Business Accelerators, the program with the best pan-European reach, and as Top 4 European Accelerator brand in the Startup Heatmap Europe report.

"This is not your usual competition where only the top winner counts," states Chahab Nastar, Chief Innovation Officer at EIT Digital. "The 20 finalists were selected among 403 submissions, that is, they are the top 5%. They are growing fast and have great potential to become European success stories. The jury saw outstanding qualities in the 5 companies that came on top. We now welcome them into the EIT Digital Accelerator and will give them dedicated pan European support for customer acquisition and fundraising. We want them to become dominant companies in their respective markets”.

“This is a very prestigious award. Having followed the pitches of the other finalists made me feel humble to be selected with these great companies that use technology to make a difference in a wide range of sectors. This shows the enormous potential of European technology companies, which we sometimes forget. I am very proud of our team that works hard and passionately to develop solutions that impact the lives of people with neurological disorders” comments icometrix CEO, Wim Van Hecke. “I would like to dedicate this award to our team and all people with neurological disorders”.

On the collaboration with the EIT Digital Accelerator, Wim Van Hecke commented further that “icometrix developed a unique brain MRI and CT technology that will benefit from a strong partner with great expertise and a vast network in many European markets. We also created a COVID-19 lung CT solution, icolung, which can help many European hospitals during this pandemic.”

EIT Digital

EIT Digital is a leading European digital innovation and entrepreneurial education organization driving Europe’s digital transformation. Its way of working embodies the future of innovation through a pan-European ecosystem of over 200 top European corporations, SMEs, startups, universities, and research institutes, where students, researchers, engineers, business developers, and entrepreneurs collaborate in an open innovation setting. This pan-European ecosystem is located in Amsterdam, Berlin, Braga, Budapest, Brussels, Eindhoven, Edinburgh, Helsinki, London, Madrid, Milano, Munich, Nice, Paris, Rennes, Stockholm, Trento, and San Francisco.

icometrix (Leuven, Belgium; Chicago, USA) strives for data-driven insights and personalized patient care, supported by artificial intelligence. icometrix has an extensive portfolio to assist healthcare with various challenges; icobrain extracts data from brain MRI and CT scans for the radiological reporting and clinical management of neurological disorders such as multiple sclerosis, brain trauma, epilepsy, dementia, and Alzheimer's disease. icompanion helps people with MS and their care team to monitor clinical symptoms and treatments efficiently and objectively. icolung addresses the COVID-19 pandemic by measuring lung involvement on chest CT.

Today, icometrix is internationally active and integrated into more than 100 clinical practices. In addition, icometrix collaborates with healthcare providers and pharmaceutical companies on the evaluation of drug research for neurological disorders.

More info: https://icometrix.com/